Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Lung Neoplasms 12Head and Neck Neoplasms 10Rectal Neoplasms 8Prostatic Neoplasms 7Mouth Neoplasms 5Glioblastoma 5Esophageal Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Neoplasm Metastasis 4Hypopharyngeal Neoplasms 4Gliosarcoma 4Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Neuroblastoma 3Neoplasms 3Laryngeal Neoplasms 3Brain Neoplasms 3Uterine Cervical Dysplasia 2Turcot syndrome 2Tongue Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2

Interventions

polyphenon E 1mirabegron 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1TroVax 1Radiotherapy 1Needles 1Electroacupuncture 1Doxazosin 1Docetaxel 1Celecoxib 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Hyperplasia × Celecoxib × Clear all
NCT01678313 2014-07-15

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

Buddhist Tzu Chi General Hospital

Phase 2 Completed
140 enrolled 10 charts
Genitourinary

Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡